Moleculin Biotech (MBRX) Enrolled It First Two Patients In European Clinical Trial - Maxim
Tweet Send to a Friend
Maxim Group analyst Jason McCarthy reiterated a Buy rating and $3.00 price target on Moleculin Biotech (NASDAQ: MBRX) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
